SSY Group (HKG:2005) received approval from China's National Medical Products Administration for the production and registration of Letermovir Injection, according to a Thursday Hong Kong bourse filing.
The 240-mg injectable drug is used to prevent cytomegalovirus infection and disease in adult recipients who are CMV-seropositive after allogeneic hematopoietic stem cell transplantation.